The bill amends various sections of Alaska's pharmacy laws to enhance the role of pharmacists in prescribing and administering medications, particularly in the context of pain management and opioid use. Key provisions include the requirement for pharmacists to complete training in pain management and opioid addiction as part of their licensure and continuing education. Specifically, the bill mandates that licensed pharmacists who prescribe or administer controlled substances must register with the controlled substance prescription database. Additionally, it establishes standards for independent prescribing of vaccines and opioid overdose drugs, and it allows pharmacists to provide patient care services under collaborative practice agreements with non-pharmacist practitioners.

Furthermore, the bill introduces new qualifications for licensure by examination, including education in pain management and opioid use, and it updates the definition of the "practice of pharmacy" to include the independent prescribing and administration of drugs. It also clarifies that pharmacists must recognize their professional limits and consult with other practitioners when necessary. The changes aim to improve patient care and ensure that pharmacists are adequately trained to handle the complexities of medication management, particularly in the context of the ongoing opioid crisis. The act is set to take effect on January 1, 2026.

Statutes affected:
HB0195A, AM HB 195, introduced 04/15/2025: 08.80.030, 17.30.200, 08.80.168, 17.22.020, 17.20.085, 08.80.159, 08.80.110, 08.80.145, 08.80.165, 08.80.337, 08.80.480